Document Classification

Section Type: RESULTS

Text: For VBT and paclitaxel-eluting stents, respectively, the number of events and 9-month rates for ischemic target lesion revascularization were 27 (13. 9 %) vs 12 (6. 3 %) (relative risk [RR], 0. 45 ; 95 % confidence interval [CI], 0. 24-0. 86 ; P =. 01) ; for ischemic target vessel revascularization, 34 (17. 5 %) vs 20 (10. 5 %) (RR, 0. 60 ; 95 % CI, 0. 36-1. 00 ; P =. 046) ; and for overall major adverse cardiac events, 39 (20. 1 %) vs 22 (11. 5 %) (RR, 0. 57 ; 95 % CI, 0. 35-0. 93 ; P =. 02), with similar rates of cardiac death or myocardial infarction (10 [5. 2 %] vs 7 [3. 7 %] ; RR, 0. 71 ; 95 % CI, 0. 28-1. 83 ; P =. 48) and target vessel thrombosis (5 [2. 6 %] vs 3 [1. 6 %] ; RR, 0. 61 ; 95 % CI, 0. 15-2. 50 ; P =. 72).